Boehringer and CDR-Life announce data from geographic atrophy treatment trial

Boehringer Ingelheim and CDR-Life have announced positive results from the Phase I trial of BI 771716, a new treatment for geographic atrophy (GA), a severe form of late-stage dry age-related macular degeneration (AMD). BI 771716 is an investigational antibody fragment designed to preserve vision in GA patients.

The trial evaluated the safety, tolerability, and pharmacokinetics of BI 771716 in patients over 50. Conducted in two phases—single rising dose (SRD) and multiple dose (MD)—the SRD phase involved a single injection, while the MD phase included two injections spaced four weeks apart. The primary endpoint was the incidence of ocular dose-limiting events (DLEs), with secondary endpoints including adverse events (AEs) and the maximum serum concentration (Cmax) after a single dose.

The trial successfully met its primary safety endpoint for both phases. A Phase II trial is now being planned. BI 771716, developed with CDR-Life, utilizes advanced technology for optimized retinal penetration to address GA.